July 31, 2018 05:05 PM EDT

Hammered by a series of setbacks, NewLink axes staff (again) and circles its wagons around troubled IDO program

John Carroll

Editor & Founder

Three months after NewLink Genetics scrapped a combination program for its IDO pathway drug indoximod in the general rout that followed the failure of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Hammered by a series of setbacks, NewLink axes staff (again) and circles its wagons around troubled IDO program

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Ham­mered by a se­ries of set­backs, NewLink ax­es staff (again) and cir­cles its wag­ons around trou­bled IDO pro­gram

Editor & Founder

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Hammered by a series of setbacks, NewLink axes staff (again) and circles its wagons around troubled IDO program